Climate Justice Last Verified: 2026-07-30 | Author: Kateule Sydney | Published by E-cyclopedia Resources | Topic: Climate Justice Climate justice recognizes that climate impacts are not felt equally across communities Summary: Climate justice recognises that climate change affects communities differently, with those least responsible often bearing the heaviest burden. It demands fair distribution of climate burdens and benefits, inclusive decision-making, and accountability through international law, with the ICJ's 2025 Advisory Opinion and UNGA Resolution marking a turning point in legal recognition. Table of Contents Chapter 1 — What is Climate Justice: Dimensions and Definitions Chapter 2 — The ICJ Advisory Opinion: A Legal Turning Point for Climate Justice Chapter 3 — Loss and Damage: The Financial Pillar of Climate Justice Chapter 4 — Climate Litigation: Holding Polluters Accountable FAQ Chapter 1 — W...
Precision Oncology
Last Verified: 2026-07-30 | Author: Kateule Sydney | Published by E-cyclopedia Resources | Topic: Precision Oncology
Genomic profiling and personalized cancer treatment
Summary: Precision oncology tailors cancer care to individual genetic, molecular, and environmental factors, moving beyond one-size-fits-all approaches. By leveraging comprehensive genomic profiling, AI-driven pathology, and molecular tumor boards, this paradigm improves response rates and progression-free survival in advanced solid tumors, offering new hope for patients with previously limited options.
```Table of Contents
Chapter 1 — The Precision Oncology Paradigm: From Genomics to Personalized Care
1.1 Defining Precision Oncology and Its Core Components
Precision oncology represents a fundamental shift in cancer care, moving from treatment based on tumor location to therapies guided by the unique molecular and genetic profile of each patient's cancer. This approach considers individual genetic, molecular, lifestyle, and environmental factors to enhance prevention, early detection, diagnosis, and treatment through tumor profiling and targeted therapies. The paradigm has been validated through regulatory approvals of tumor-agnostic biomarkers, including pembrolizumab for microsatellite instability-high tumors and larotrectinib for NTRK fusion-positive cancers.
Core components of precision oncology include:
- Comprehensive genomic profiling (CGP): Next-generation sequencing of tissue and blood to identify actionable alterations
- Molecular tumor boards (MTB): Multidisciplinary expert teams interpreting complex genomic data and recommending tailored therapies
- Liquid biopsy: Minimally invasive real-time analysis of tumor-derived biomarkers from blood for dynamic monitoring
- AI and spatial proteomics: Advanced computational tools to characterize tumor heterogeneity and predict treatment response
Case Study — Implementing Precision Oncology in North Africa: Dr. Yosr Hamdi, a biologist and researcher at Institut Pasteur de Tunis, has been integrating genomic medicine and molecular diagnostics into the Tunisian healthcare system since completing her PhD. She now leads the Genome Tunisia Collaborative Alliance (GTCA) and the PerMediNA Consortium to investigate cancer genomics in African populations and implement precision oncology across North Africa. Her work demonstrates how precision oncology can be adapted to resource-constrained settings through strategic partnerships and capacity building.
Chapter 2 — The ROME Trial: Randomized Evidence for Genomically Guided Therapy
2.1 The Landmark ROME Trial: A Turning Point for Precision Oncology
Until recently, randomized evidence supporting the clinical superiority of precision oncology over standard therapies remained limited. The ROME trial, published in Nature Medicine in 2025, changed this landscape. This multicenter, randomized phase 2 study compared tailored treatment (TT) to standard of care (SoC) in 400 patients with advanced solid tumors who had progressed after one or two lines of therapy. Comprehensive genomic profiling on tissue and blood was performed to identify actionable alterations, and all cases underwent systematic molecular tumor board review.
Key ROME trial results:
- Overall Response Rate: TT achieved 17.5% (including 3% complete responses) versus 10% for SoC
- Progression-Free Survival: Median PFS 3.5 months versus 2.8 months (HR = 0.66)
- 12-Month PFS Rates: 22.0% for TT versus 8.3% for SoC
- Safety: Grade ≥3 adverse events were similar (40% TT versus 52% SoC)
ROME succeeded where earlier trials like SHIVA failed by requiring fresh metastatic tissue biopsies at disease progression, employing comprehensive NGS of both tissue and blood, and mandating systematic MTB review of all cases. Treating patients based on outdated molecular profiles is akin to navigating with an old map; ROME's approach captured the tumor's current biology, not its historical state. The trial demonstrated that treatment selection often requires navigating competing biomarkers, conflicting pathway interactions, and variant allele frequencies—complexity that argues for specialized expertise in treatment selection.
Case Study — The I-PREDICT N-of-1 Trial: In a complementary precision oncology study, 70 patients with advanced poor-prognosis cancers received individualized ICI-based combinations based on tissue/ctDNA NGS and MTB review. Patients had a median of five pathogenic alterations (range 1–18), with 97% having unique molecular profiles. Higher biomarker matching scores correlated with improved outcomes: disease control rate 74% for high-matching versus 27% for low-matching, and PFS 10.4 versus 3.8 months. This highlights the importance of comprehensive matching in personalized therapy.
Chapter 3 — AI and Spatial Proteomics: Redefining Tumor Characterization
3.1 AI-Powered Digital Pathology and Spatial Proteomics in Clinical Practice
Artificial intelligence and spatial proteomics are revolutionizing how tumors are characterized, enabling cell-by-cell mapping of tumor heterogeneity and treatment resistance. These technologies address a persistent challenge in advanced disease: pinpointing metastasis-initiating and therapy-resistant subclones within the native tissue architecture that conventional histopathology and bulk genomic assays often miss.
Key AI applications in precision oncology:
- AI-based digital pathology: Deep learning models detect subtle, prognostically relevant morphologic patterns and resolve distinct cellular phenotypes on routine H&E slides
- Virtual spatial proteomics: AI models generate spatial proteomics profiles and predict expression of 40+ biomarkers directly from standard H&E-stained slides
- Single-cell spatial mapping: Advanced methods decode spatial relationships between cells that drive disease progression
- Multi-modal foundation models: Integrating histopathology with spatial transcriptomics and proteomics for a holistic view of tumor biology
Case Study — AI and Spatial Proteomics in Recurrent Melanoma: Researchers applied an integrated workflow combining AI-based digital pathology with spatial proteomics in a young patient with recurrent metastatic melanoma over an eight-year disease course. The AI model identified two spatially separated cell subpopulations within the primary lesion—one of which was identified as the likely metastatic driver. Spatial proteomics revealed increased kinases associated with target-drug resistance and identified augmented glycolytic signaling and mitochondrial metabolism as drivers of melanoma progression. The integrated analysis suggested that targeted therapies may provide limited benefit, while combination with metabolic inhibitors could represent a more effective treatment option.
Chapter 4 — Overcoming Barriers to Implementation and Access
4.1 Infrastructure, Equity, and Ethical Challenges in Precision Oncology
Despite remarkable therapeutic advances, widespread implementation of precision oncology faces significant challenges. Infrastructure requirements include coordinated molecular profiling with rapid turnaround, expert MTB evaluation, and access to multiple targeted agents—resources unavailable in many settings. Additionally, clinicians report inconsistent knowledge and skills in interpreting biomarker results, making treatment recommendations, and communicating uncertainty to patients.
Critical implementation barriers and emerging solutions:
- Clinical knowledge gaps: Limited skills in counseling patients about implications, setting expectations, and communicating rationale for treatment selection
- Logistical constraints: Long turnaround times, lack of insurance coverage, and fragmented reimbursement policies
- Health equity disparities: High costs of comprehensive genomic profiling and targeted therapies create access barriers, particularly in LMICs
- Ethical challenges: Managing probabilistic risk information, mitigating bias from AI-driven diagnostics, and establishing robust governance for longitudinal molecular data
Case Study — PrOPA 360° AI Tele-Oncology Platform: Bulgaria piloted the PrOPA platform, an AI-enhanced virtual comprehensive cancer center to address limited access to multidisciplinary oncology expertise outside major cities. The system allows structured case submissions, virtual tumor board reviews, and integrated decision support through an AI-driven clinical reasoning engine. Since launch, PrOPA has been validated in Bulgaria and is undergoing multicenter evaluation in Cyprus, Portugal, and India. The platform demonstrates how AI can democratize access to precision oncology expertise, particularly in underserved regions facing workforce shortages.
FAQ: Precision Oncology Questions Answered
What is precision oncology and how does it differ from traditional cancer treatment?
Precision oncology tailors cancer treatment to the unique genetic and molecular profile of each patient's tumor, rather than treating based solely on tumor location. It uses genomic profiling, biomarker testing, and expert molecular tumor boards to match patients with targeted therapies most likely to benefit them.
What does the ROME trial tell us about precision oncology's effectiveness?
The ROME trial demonstrated that genomically guided therapy improves overall response rates (17.5% vs 10%) and progression-free survival (HR 0.66) compared to standard care in advanced solid tumors. It provides the first robust randomized evidence supporting precision oncology's clinical benefit.
What are the main barriers to implementing precision oncology?
Key barriers include limited clinician knowledge and skills in biomarker interpretation, long turnaround times for genomic testing, lack of insurance coverage, high costs, and uneven access to molecular tumor board expertise. These challenges are particularly acute in low- and middle-income countries.
Comments
Post a Comment